09:37 AM EST - Odyssey Group International Inc : Announces the launch of a concept phase to develop an intra-nasal field-deliverable nerve agent antidote. Chemical warfare using organophosphate nerve agents is a threat worldwide. Odyssey’s unique breath-propelled intranasal device is being developed to increase brain drug exposure in minutes. The projected benefits of the novel Oxime-Intranasal combination include almost immediate exposure of the Central Nervous System, enhanced brain cell protection with less drug required given the targeted approach, lower risk for infection with no injection site exposure, and a painless and complete dosing protocol.se brain drug exposure in minutes. Odyssey Group International Inc
shares O.ODYY are trading unchanged at $0.29.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ODYY&qmodStoryID=5256735161763492